Currently, only RAS-mutation status is used routinely as a negative predictive marker to avoid treatment with anti-EGFR agents in patients with metastatic CRC, but unfortunately a RAS-wild-type status does not guarantee a response. This evidence concerns the gene EGFR and colorectal carcinoma.